Clinical Trial Update: Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer [Phase 1]

View source ↗

Summary

Phase I dose-finding study of SSR97225 in patients with refractory cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SSR97225

Snippet

Sponsor: Sanofi | Conditions: Neoplasms | Phase 1 | Status: TERMINATED